Ninety percent of the various types of KRAS mutations occur in codons 12 and 13, which leads to constitutive activation of epidermal growth factor receptor (EGFR) downstream pathways in CRC cells, resulting in cell proliferation, migration, and metastasis, evasion of apoptosis, or angiogenesis. This evidence concerns the gene KRAS and colorectal carcinoma.